Table of Contents
ISRN Oncology
Volume 2012 (2012), Article ID 756591, 6 pages
http://dx.doi.org/10.5402/2012/756591
Review Article

Metastatic Squamous Cell Carcinoma of the Anus: Time for a Shift in the Treatment Paradigm?

Department of Medicine, Royal Marsden Hospital, London and Surrey, UK

Received 10 January 2012; Accepted 29 January 2012

Academic Editor: H. Al-Ali

Copyright © 2012 Alice Dewdney and Sheela Rao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. http://www.fascrs.org/patients/conditions/anal_cancer/.
  2. L. G. Johnson, M. M. Madeleine, L. M. Newcomer, S. M. Schwartz, and J. R. Daling, “Anal cancer incidence and survival: the Surveilance, epidemiology, and end results experience, 1973–2000,” Cancer, vol. 101, no. 2, pp. 281–288, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. N. F. Crum-Cianflone, K. H. Hullsiek, V. C. Marconi et al., “Anal cancers among HIV-infected persons: HAART is not slowing rising incidence,” AIDS, vol. 24, no. 4, pp. 535–543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. R. Daling, M. M. Madeleine, L. G. Johnson et al., “Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer,” Cancer, vol. 101, no. 2, pp. 270–280, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. D. P. Ryan and R. J. Mayer, “Anal carcinoma: histology, staging, epidemiology, treatment,” Current Opinion in Oncology, vol. 12, no. 4, pp. 345–352, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. http://www.nccn.org/professionals/physician_gls/pdf/anal.pdf.
  7. B. Sischy, R. L. Scotte Doggett, J. M. Krall et al., “Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group Study No. 8314,” Journal of the National Cancer Institute, vol. 81, no. 11, pp. 850–856, 1989. View at Google Scholar · View at Scopus
  8. J. Northover, R. Glynne-Jones, D. Sebag-Montefiore et al., “Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I),” British Journal of Cancer, vol. 102, no. 7, pp. 1123–1128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. R. James, S. Wan, R. Glynne-Jones et al., “A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II),” Journal of Clinical Oncology, vol. 27, no. 18s, supplement, abstract LBA4009, 2009. View at Google Scholar
  10. H. Bartelink, F. Roelofsen, F. Eschwege et al., “Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups,” Journal of Clinical Oncology, vol. 15, no. 5, pp. 2040–2049, 1997. View at Google Scholar · View at Scopus
  11. http://seer.cancer.gov/publications/survival/surv_anus.pdf.
  12. J. M. A. Northover, S. J. Arnott, D. Cunningham et al., “Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin,” Lancet, vol. 348, no. 9034, pp. 1049–1054, 1996. View at Publisher · View at Google Scholar
  13. N. Wilking, N. Petrelli, L. Herrera, and A. Mittelman, “Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal,” Cancer Chemotherapy and Pharmacology, vol. 15, no. 3, pp. 300–302, 1985. View at Google Scholar · View at Scopus
  14. J. D. Hainsworth, H. A. Burris III, A. A. Meluch, M. N. Baker, L. H. Morrissey, and F. Anthony Greco, “Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial,” Cancer, vol. 92, no. 3, pp. 642–649, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Jhawer, S. Mani, M. Lefkopoulou et al., “Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282,” Investigational New Drugs, vol. 24, no. 5, pp. 447–454, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. T. R. J. Evans, J. L. Mansi, and J. P. Glees, “Response of metastatic anal carcinoma to single agent carboplatin,” Clinical Oncology, vol. 5, no. 1, pp. 57–58, 1993. View at Google Scholar · View at Scopus
  17. W. B. Fisher, K. D. Herbst, J. E. Sims, and C. F. Critchfield, “Metastatic cloacogenic carcinoma of the anus: sequential responses to adriamycin and cis-dichlorodiammineplatinum(II),” Cancer Treatment Reports, vol. 62, no. 1, pp. 91–97, 1978. View at Google Scholar · View at Scopus
  18. S. Zimm and L. Wampler, “Response of metastatic cloacogenic carcinoma to treatment with semustine,” Cancer, vol. 48, no. 12, pp. 2575–2576, 1981. View at Google Scholar · View at Scopus
  19. D. V. Golub, A. C. Civelek, and V. R. Sharma, “Case report; a regimen of taxol, ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal,” Chemotherapy Research and Practice, vol. 2011, Article ID 163736, 6 pages, 2011. View at Publisher · View at Google Scholar
  20. F. Grifalchi, A. Padovani, F. Romeo, C. Trinca, L. Moscetti, and E. Cortesi, “Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report,” Tumori, vol. 87, no. 1, pp. 58–59, 2001. View at Google Scholar · View at Scopus
  21. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  22. C. Faivre, P. Rougier, M. Ducreux et al., “5-Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer,” Bulletin du Cancer, vol. 86, no. 10, pp. 861–865, 1999. View at Google Scholar · View at Scopus
  23. R. Khater, M. Frenay, and J. Bourry, “Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases,” Cancer Treatment Reports, vol. 70, no. 11, pp. 1345–1346, 1986. View at Google Scholar · View at Scopus
  24. J. A. Ajani, C. H. Carrasco, D. E. Jackson, and S. Wallace, “Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal,” American Journal of Medicine, vol. 87, no. 2, pp. 221–224, 1989. View at Google Scholar · View at Scopus
  25. I. A. Jaiyesimi and R. Pazdur, “Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal,” American Journal of Clinical Oncology, vol. 16, no. 6, pp. 536–540, 1993. View at Google Scholar · View at Scopus
  26. D. Cunningham, N. Starling, S. Rao et al., “Capecitabine and oxaliplatin for advanced esophagogastric cancer,” New England Journal of Medicine, vol. 358, no. 1, pp. 36–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Pfeiffer, J. P. Mortensen, B. Bjerregaard et al., “Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer,” European Journal of Cancer, vol. 42, no. 16, pp. 2738–2743, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. M. J. Greenall, G. B. Magill, S. H. Q. Quan, and J. J. DeCosse, “Recurrent epidermoid cancer of the anus,” Cancer, vol. 57, no. 7, pp. 1437–1441, 1986. View at Google Scholar · View at Scopus
  29. S. De Dosso, V. Martin, E. Zanellato, M. Frattini, and P. Saletti, “Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma,” Tumori, vol. 96, no. 4, pp. 627–628, 2010. View at Google Scholar · View at Scopus
  30. N. Lukan, P. Ströbel, A. Willer et al., “Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status,” Oncology, vol. 77, no. 5, pp. 293–299, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. L. K. Phan and P. M. Hoff, “Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case,” Diseases of the Colon and Rectum, vol. 50, no. 3, pp. 395–398, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. T. M. Pawlik, A. L. Gleisner, T. W. Bauer et al., “Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis,” Annals of Surgical Oncology, vol. 14, no. 10, pp. 2807–2816, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Charnley, A. Choudhury, P. Chesser, R. A. Cooper, and D. Sebag-Montefiore, “Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy,” British Journal of Cancer, vol. 92, no. 7, pp. 1221–1225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Paliga, R. Onerheim, A Gologan et al., “EGFR expression in invasive anal carcinoma,” Journal of Clinical Oncology, vol. 29, no. 4, supplement, abstract 412, 2011. View at Google Scholar
  35. L. H. Lê, R. Chetty, and M. J. Moore, “Epidermal growth factor receptor expression in anal canal carcinoma,” American Journal of Clinical Pathology, vol. 124, no. 1, pp. 20–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Alvarez, A. Perry, B. R. Tan, and H. L. Wang, “Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification,” Modern Pathology, vol. 19, no. 7, pp. 942–949, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Walker, L. Abramowitz, D. Benabderrahmane et al., “Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus,” Human Pathology, vol. 40, no. 11, pp. 1517–1527, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Paliga, G. Chong, R. Onerheim et al., “KRAS and EGFR gene mutation status in anal canal carcinoma,” in Proceedings of the Gastrointestinal Cancers Symposium, Abstract 352, 2010.
  39. M. W. Saif, E. Kontny, K. N. Syrigos, and A. Shahrokni, “The role of EGFR inhibitors in the treatment of metastatic anal canal carcinoma: a case series,” Journal of Oncology, vol. 2011, Article ID 125467, 5 pages, 2011. View at Publisher · View at Google Scholar
  40. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck,” New England Journal of Medicine, vol. 354, no. 6, pp. 567–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Borghaei, C. J. Langer, M. Millenson et al., “Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017,” Journal of Thoracic Oncology, vol. 3, no. 11, pp. 1286–1292, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Hitt et al., “Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck,” Annals of Oncology. In press.
  43. J. A. Ajani, K. A. Winter, L. L. Gunderson et al., “Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11),” Cancer, vol. 116, no. 17, pp. 4007–4013, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Edelman and P. A. S. Johnstone, “Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 1, pp. 206–211, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Lampejo, D. Kavanagh, J. Clark et al., “Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review,” British Journal of Cancer, vol. 103, no. 12, pp. 1858–1869, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Holm, E. Skovlund, H. Skomedal, V. A. Flørenes, and G. Tanum, “Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas,” Histopathology, vol. 39, no. 1, pp. 43–49, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. C. S. Wong, M. S. Tsao, V. Sharma, W. B. Chapman, M. Pintilie, and B. J. Cummings, “Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal,” International Journal of Radiation Oncology Biology Physics, vol. 45, no. 2, pp. 309–314, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. S. R. Bonin, T. F. Pajak, A. H. Russell et al., “Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04,” Cancer, vol. 85, no. 6, pp. 1226–1233, 1999. View at Publisher · View at Google Scholar
  49. J. A. Ajani, X. Wang, J. G. Izzo et al., “Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation,” Digestive Diseases and Sciences, vol. 55, no. 4, pp. 1098–1105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. N. A. Shepherd, J. H. Schofefield, S. B. Love, J. England, and J. M. A. Northover, “Prognositc factors in anal squamous carcinoma: a multivariate analysis of clincal, pathological and flow cytometric parameters in 235 cases,” Histopathology, vol. 16, no. 6, pp. 545–555, 1990. View at Google Scholar · View at Scopus